Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI)
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI)
复制标题
DOI：
10.1093/annonc/mdt501
复制
发表时间：
2013-12-01
影响因子：
50.5
通讯作者：
Cherny, N. I.
中科院分区：
文献类型：
--
作者：
Cleary, J.;Simha, N.;Cherny, N. I.
印度是世界上最大的民主国家，阿片类药物的控制权由国家和邦政府分配。尽管全球类阿片消费量有所增加，但消费量并未以同样的速度增长。这是印度癌症患者对阿片类药物的可用性和可及性的第一项全面研究。据报道，印度 24 个邦和德里周边行政区用于治疗癌症疼痛的阿片类药物的供应和可及性数据。这项调查覆盖了全国 11.89 亿人口中的约 10.61 亿人（89%）。无一例外，印度各地的阿片类药物供应量仍然很低。即使阿片类药物已列入处方药，也常常无法获得。全国范围内普遍存在的过度监管严重损害了准入。
India is the world's largest democracy with control of opioids divided between the national and state governments. While the global consumption of opioids has increased, the consumption has not increased at the same rate. This is the first comprehensive study of opioid availability and accessibility for cancer patients in India. Data are reported on the availability and accessibility of opioids for the management of cancer pain in 24 of the states that make up India and the Administrative area around Delhi. About 1061 million of the nation's 1189 million people (89%) are covered by this survey. Without exception, opioid availability continues to be low throughout all of India. Even when opioids are on formulary, they are often unavailable. Access is significantly impaired by widespread over-regulation that continues to be pervasive across the nation.